Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

NCT04361708 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Adenocarcinoma

Interventions

DRUG: Oxaliplatin
DRUG: Docetaxel
DRUG: Leucovorin
DRUG: Irinotecan
DRUG: 5-Fluorouracil

Sponsor

University of Chicago